Hexarelin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Hexarelin

Also known as: GHRP-6 analog, His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2, Examorelin, EP23905, MF-6003

Synthetic growth hormone-releasing peptide (GHRP); Growth hormone secretagogue (GHS); GHS receptor agonist

Not FDA-approvedLast updated: October 31, 2026Based on 39 peer-reviewed studies

What it is

Hexarelin is a peptide people use to stimulate growth hormone release for body composition, recovery, and aging. It also shows potential for cardiovascular protection in animal studies, acting directly on heart tissue. Not FDA-approved; likely WADA-prohibited; most human evidence comes from GH diagnostic studies rather than therapeutic trials.

The scientific side

Hexarelin is a synthetic hexapeptide (His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2), a non-natural superanalog of GHRP-6, that acts as a potent agonist at growth hormone secretagogue receptors (GHS-R1a) present at both the pituitary and hypothalamic levels, as well as in peripheral tissues including heart, adrenal glands, ovary, testis, lung, and skeletal muscle. It stimulates GH release via a mechanism distinct from GHRH, likely involving counteraction of somatostatinergic activity and/or partial GHRH-mediated pathways. Hexarelin also stimulates prolactin and ACTH/cortisol secretion, and its effect on the HPA axis appears to involve stimulation of arginine vasopressin (AVP) release rather than CRH. Beyond neuroendocrine effects, hexarelin exerts GH-independent cardiovascular actions via specific cardiac GHS receptors, anti-apoptotic and cytoprotective effects in cardiomyocytes, and PPARγ-activating effects through CD36. Neuroprotective properties have been demonstrated in several in vitro and animal models.

Class: Synthetic growth hormone-releasing peptide (GHRP); Growth hormone secretagogue (GHS); GHS receptor agonist

Not FDA-approvedLow researchHormonesGrowth hormone-releasing peptide (GHRP)

At a glance

What it isA synthetic 6-amino-acid growth hormone-releasing peptide (GHRP), also called examorelin.
FDA statusNot approved for any use. Not named on FDA's compounding safety-risk page.
Used forStrong growth hormone release; studied for growth hormone deficiency and heart function.
Human evidenceSmall 1990s-2000s studies in healthy adults, children and heart patients.
Half-lifeNot reported in humans. About 2 hours after IV dosing in dogs.
Banned in sportYes. WADA names "examorelin (hexarelin)" under S2.2.4, prohibited at all times.

What is Hexarelin?

Hexarelin (examorelin) is a synthetic hexapeptide, a growth hormone-releasing peptide in the same family as GHRP-6 and Ipamorelin. Early human studies showed it released growth hormone after IV, under-the-skin, nasal and even oral doses.

It is less selective than ipamorelin: each dose also raises the stress hormones ACTH and cortisol, and prolactin.

Sources: [1] [2]

How does it work?

Hexarelin activates the ghrelin receptor (GHS-R1a), triggering a large growth hormone pulse. In people with growth hormone deficiency caused by a disconnection between the hypothalamus and pituitary, it barely worked, which suggests its effect depends on the hypothalamus.

It also binds CD36, a receptor in heart tissue, which is how researchers explain its direct heart effects in animals.

Pharmacokinetics

Half-lifeNot reported in humans; terminal half-life about 120 minutes after IV dosing in dogs
MetabolismNot characterized in humans
ClearanceNot characterized in humans
RouteActive by IV, subcutaneous, nasal and oral routes in humans; usually injected under the skin

Sources: [3] [4] [5] [1]

Is it FDA-approved?

No. Hexarelin has never been approved anywhere for any use.

FDA's page of compounding substances with significant safety risks does not name hexarelin, and it has not been on a Pharmacy Compounding Advisory Committee agenda. Related GHRPs (GHRP-2, GHRP-6) are on FDA's Category 2 list.

  • WADA: S2.2.4 Growth hormone releasing factors (named as "examorelin (hexarelin)" among GHRPs; prohibited at all times)

Sources: [6] [7]

History

Hexarelin was studied intensively in the 1990s. A 1994 study showed it released growth hormone by four routes of administration, and dose-response studies followed in adults and children.

Researchers tested it in children with short stature and growth hormone deficiency, in older adults, and in heart patients, where it acutely improved heart pumping. It was never developed into an approved drug and is now sold as a research peptide.

Sources: [1] [8] [3] [9]

Regulatory timeline

  1. September 29, 2023FDA places the related GHRPs GHRP-2 and GHRP-6 in Category 2 (503B). Hexarelin is not named. Source
  2. As of April 2026FDA's compounding safety-risk page still does not name hexarelin, and it has not been on an advisory committee agenda. Source

Side effects

Each injection briefly raises other pituitary hormones. In healthy adults, 2 micrograms/kg IV roughly doubled ACTH and raised cortisol by about 24%. Prolactin rose by up to about 180% at higher doses.

With repeated use these spikes fade. After 16 weeks of twice-daily injections in older adults, the authors concluded that "over-stimulation of the pituitary adrenal axis and prolactin secretion do not occur." People with pituitary or adrenal conditions should get medical advice before using it.

Common

  • Brief rises in ACTH and cortisol after each dose
  • Brief rise in prolactin after each dose

Who should not use it

  • No established contraindications: hexarelin never completed development.
  • Competitive athletes: Prohibited at all times under WADA S2.2.4 (growth hormone releasing factors), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
  • Pituitary or adrenal disorders: each dose raises ACTH and cortisol; in Cushing's disease the ACTH rise was about 7 times that of CRH.
  • Active cancer: it raises growth hormone, a growth factor.

Small physiology studies in healthy adults (Ghigo 1997, Massoud 1996) and a 16-week study in older adults (Rahim 1998, 1999).

Sources: [2] [8] [10]

What does the research show?

In a 16-week study of twice-daily injections (1.5 micrograms/kg) in older adults, the growth hormone response to a test dose fell from 19.1 to 10.5 µg/L·h, about 45%, and recovered fully 4 weeks after stopping. IGF-1, body fat, lean mass and bone density did not change.

In adults with growth hormone deficiency and in healthy controls, a single dose acutely raised left ventricular ejection fraction, a measure of heart pumping. Response varies with age, and the GH response is weaker in people with pituitary disease.

Studied for

  • Growth hormone deficiency and short stature in children
  • Growth hormone release in older adults (16-week study)
  • Heart function in adults with GH deficiency and in heart failure (single-dose studies)

Sources: [11] [9] [12] [13]

FAQ

Does Hexarelin raise cortisol and prolactin?

Yes, briefly after each dose: in healthy adults ACTH roughly doubled and cortisol rose about 24%, and prolactin rose up to about 180%. With 16 weeks of use these rises faded.

Sources: [2] [8] [10]

Does Hexarelin stop working over time?

Partly. After 16 weeks of twice-daily injections the growth hormone response fell about 45%, and it recovered 4 weeks after stopping.

Sources: [11]

Does Hexarelin raise IGF-1?

Not in the 16-week study: IGF-1 did not change significantly.

Sources: [11]

Is Hexarelin FDA-approved?

No, and FDA's compounding safety-risk page does not name it.

Sources: [6]

Does Hexarelin affect the heart?

In single-dose studies it acutely raised heart pumping (ejection fraction). It binds CD36, a receptor in heart tissue.

Sources: [9] [4]

Is Hexarelin banned in sport?

Yes. The 2026 WADA Prohibited List names "examorelin (hexarelin)" under S2.2.4, prohibited at all times.

Sources: [14]

Citations

  1. Ghigo E, et al. Growth hormone-releasing activity of hexarelin after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 1994. PMID 8126144
  2. Ghigo E, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997. PMID 9253314
  3. Loche S, et al. The effect of hexarelin on growth hormone secretion in patients with GH deficiency. J Clin Endocrinol Metab 1995. PMID 7673411
  4. Bodart V, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002. PMID 11988484
  5. Roumi M, et al. Radioimmunoassay for hexarelin and its pharmacokinetic studies. Peptides 1995. PMID 8545255
  6. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  7. FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (agenda). fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  8. Massoud AF, et al. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab 1996. PMID 8954038
  9. Bisi G, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999. PMID 10528131
  10. Rahim A, et al. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf) 1999. PMID 10341859
  11. Rahim A, et al. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998. PMID 9589671
  12. Arvat E, et al. The GH, prolactin, ACTH and cortisol responses to hexarelin undergo different age-related variations. Eur J Endocrinol 1997. PMID 9437229
  13. Maccario M, et al. Impact of two or three daily subcutaneous injections of hexarelin on 24-h GH, prolactin, ACTH and cortisol secretion. Eur J Endocrinol 2002. PMID 11888836
  14. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Administration & storage

Administration
Intravenous (i.v.) bolus — used in multiple human clinical studies (PMID: 81261441214494110469018108864889062497928593992310489425393104048258954038)Subcutaneous (s.c.) injection — used in human studies including 16-week twice-daily protocol (PMID: 812614495896711034185910197083)Intranasal administration — evaluated in human volunteers and children (PMID: 81261447955465)Oral administration — evaluated in human volunteers with low bioavailability (0.3%) (PMID: 812614411578108)Intraperitoneal (i.p.) injection — used in mouse studies (PMID: 3487133642619489)
Storage
No storage conditions for hexarelin are described in any of the reviewed abstracts.
Cautions
Hexarelin stimulates ACTH and cortisol secretion acutely in humans; prolonged or high-dose use could theoretically affect the HPA axis, though one 16-week twice-daily s.c. study found no significant overactivation of the pituitary-adrenal axis.,Hexarelin stimulates prolactin release in humans; concerns about repeated episodes of transient hyperprolactinaemia with long-term therapy have been noted, though not confirmed as clinically significant in a 16-week study.,Partial, reversible desensitization of the GH response has been documented with chronic twice-daily s.c. administration over 16 weeks; this may limit long-term therapeutic utility.,Oral bioavailability is very low (0.3%), and intestinal degradation by proteases is a known pharmacological limitation; permeation enhancers investigated in animal studies did not consistently improve hexarelin absorption.,Hexarelin is listed among unregulated performance-enhancing peptides used via self-administration, with uncertainty around product composition, dose, and purity in unregulated supply chains. Sterile technique is essential for any injectable administration.,No long-term human safety data on cancer incidence, mortality, or other endpoints are available for hexarelin specifically; general GHS safety data are limited.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. One review notes absence of regulatory approval for physique- or performance-related indications; another notes strict FDA criteria exist for GH use…

WADA

Not stated in reviewed literature — requires manual verification. One review classifies hexarelin among performance-enhancing peptides modulating the GH-IGF1 axis, but does not explicitly state WADA prohibition status.

Health Canada

Not stated in reviewed literature — requires manual verification.